Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
<h4>Background</h4>The impact on carriage and optimal schedule for primary vaccination of older children with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) are unknown.<h4>Methods</h4>600 Kenyan children aged 12-59 months wer...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0085459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331849207218176 |
|---|---|
| author | Laura L Hammitt John Ojal Mahfudh Bashraheil Susan C Morpeth Angela Karani Ahsan Habib Dorota Borys David Goldblatt J Anthony G Scott |
| author_facet | Laura L Hammitt John Ojal Mahfudh Bashraheil Susan C Morpeth Angela Karani Ahsan Habib Dorota Borys David Goldblatt J Anthony G Scott |
| author_sort | Laura L Hammitt |
| collection | DOAJ |
| description | <h4>Background</h4>The impact on carriage and optimal schedule for primary vaccination of older children with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) are unknown.<h4>Methods</h4>600 Kenyan children aged 12-59 months were vaccinated at days 0, 60 and 180 in a double-blind randomized controlled trial according to the following vaccine sequence: Group A: PHiD-CV, PHiD-CV, diphtheria/tetanus/acellular pertussis vaccine (DTaP); Group B: PHiD-CV, DTaP, PHiD-CV; Group C: hepatitis A vaccine (HAV), DTaP, HAV. Nasopharyngeal carriage of Streptococcus pneumoniae was measured at five timepoints. In 375 subjects, serotype-specific responses were measured by 22F-inhibition ELISA and opsonophagocytic killing assays (OPA) one month after vaccination.<h4>Results</h4>Following one dose of PHiD-CV, >90% of recipients developed IgG≥0.35 µg/mL to serotypes 1, 4, 5, 7F, 9V and 18C and OPA≥8 to serotypes 4, 7F, 9V, 18C, 23F. After a second dose >90% of recipients had IgG≥0.35 µg/mL to all vaccine serotypes and OPA≥8 to all vaccine serotypes except 1 and 6B. At day 180, carriage of vaccine-type pneumococci was 21% in recipients of two doses of PHiD-CV (Group A) compared to 31% in controls (p = 0.04). Fever after dose 1 was reported by 41% of PHiD-CV recipients compared to 26% of HAV recipients (p<0.001). Other local and systemic adverse experiences were similar between groups.<h4>Conclusions</h4>Vaccination of children aged 12-59 months with two doses of PHiD-CV two to six months apart was immunogenic, reduced vaccine-type pneumococcal carriage and was well-tolerated. Administration of PHiD-CV would be expected to provide effective protection against vaccine-type disease.<h4>Trial registration</h4>ClinicalTrials.gov NCT01028326. |
| format | Article |
| id | doaj-art-d9b911baabd1420cbb1463e37f94283c |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-d9b911baabd1420cbb1463e37f94283c2025-08-20T03:46:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8545910.1371/journal.pone.0085459Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.Laura L HammittJohn OjalMahfudh BashraheilSusan C MorpethAngela KaraniAhsan HabibDorota BorysDavid GoldblattJ Anthony G Scott<h4>Background</h4>The impact on carriage and optimal schedule for primary vaccination of older children with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) are unknown.<h4>Methods</h4>600 Kenyan children aged 12-59 months were vaccinated at days 0, 60 and 180 in a double-blind randomized controlled trial according to the following vaccine sequence: Group A: PHiD-CV, PHiD-CV, diphtheria/tetanus/acellular pertussis vaccine (DTaP); Group B: PHiD-CV, DTaP, PHiD-CV; Group C: hepatitis A vaccine (HAV), DTaP, HAV. Nasopharyngeal carriage of Streptococcus pneumoniae was measured at five timepoints. In 375 subjects, serotype-specific responses were measured by 22F-inhibition ELISA and opsonophagocytic killing assays (OPA) one month after vaccination.<h4>Results</h4>Following one dose of PHiD-CV, >90% of recipients developed IgG≥0.35 µg/mL to serotypes 1, 4, 5, 7F, 9V and 18C and OPA≥8 to serotypes 4, 7F, 9V, 18C, 23F. After a second dose >90% of recipients had IgG≥0.35 µg/mL to all vaccine serotypes and OPA≥8 to all vaccine serotypes except 1 and 6B. At day 180, carriage of vaccine-type pneumococci was 21% in recipients of two doses of PHiD-CV (Group A) compared to 31% in controls (p = 0.04). Fever after dose 1 was reported by 41% of PHiD-CV recipients compared to 26% of HAV recipients (p<0.001). Other local and systemic adverse experiences were similar between groups.<h4>Conclusions</h4>Vaccination of children aged 12-59 months with two doses of PHiD-CV two to six months apart was immunogenic, reduced vaccine-type pneumococcal carriage and was well-tolerated. Administration of PHiD-CV would be expected to provide effective protection against vaccine-type disease.<h4>Trial registration</h4>ClinicalTrials.gov NCT01028326.https://doi.org/10.1371/journal.pone.0085459 |
| spellingShingle | Laura L Hammitt John Ojal Mahfudh Bashraheil Susan C Morpeth Angela Karani Ahsan Habib Dorota Borys David Goldblatt J Anthony G Scott Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. PLoS ONE |
| title | Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. |
| title_full | Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. |
| title_fullStr | Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. |
| title_full_unstemmed | Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. |
| title_short | Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. |
| title_sort | immunogenicity impact on carriage and reactogenicity of 10 valent pneumococcal non typeable haemophilus influenzae protein d conjugate vaccine in kenyan children aged 1 4 years a randomized controlled trial |
| url | https://doi.org/10.1371/journal.pone.0085459 |
| work_keys_str_mv | AT lauralhammitt immunogenicityimpactoncarriageandreactogenicityof10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccineinkenyanchildrenaged14yearsarandomizedcontrolledtrial AT johnojal immunogenicityimpactoncarriageandreactogenicityof10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccineinkenyanchildrenaged14yearsarandomizedcontrolledtrial AT mahfudhbashraheil immunogenicityimpactoncarriageandreactogenicityof10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccineinkenyanchildrenaged14yearsarandomizedcontrolledtrial AT susancmorpeth immunogenicityimpactoncarriageandreactogenicityof10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccineinkenyanchildrenaged14yearsarandomizedcontrolledtrial AT angelakarani immunogenicityimpactoncarriageandreactogenicityof10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccineinkenyanchildrenaged14yearsarandomizedcontrolledtrial AT ahsanhabib immunogenicityimpactoncarriageandreactogenicityof10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccineinkenyanchildrenaged14yearsarandomizedcontrolledtrial AT dorotaborys immunogenicityimpactoncarriageandreactogenicityof10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccineinkenyanchildrenaged14yearsarandomizedcontrolledtrial AT davidgoldblatt immunogenicityimpactoncarriageandreactogenicityof10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccineinkenyanchildrenaged14yearsarandomizedcontrolledtrial AT janthonygscott immunogenicityimpactoncarriageandreactogenicityof10valentpneumococcalnontypeablehaemophilusinfluenzaeproteindconjugatevaccineinkenyanchildrenaged14yearsarandomizedcontrolledtrial |